Practice Management News

SAN FRANCISCO — Among prisoners, women were more likely to have opioid use disorder and more likely to receive treatment at intake compared with men, according to a poster presented here.

INDIANAPOLIS — Compared with siblings, survivors of childhood cancer have an increased risk for sleep concerns up to 30 years after diagnosis, according to a report from the Childhood Cancer Survivor Study.

A study found an increase in children diagnosed with anxiety during office visits in a recent 12-year period but a decrease in the proportion of office visits that included therapy, according to results published in Pediatrics.

INDIANAPOLIS — Transdermal exposure to near-infrared light before bed via a wearable device was linked to improved sleep, relaxation and next-day functionality compared with sham, according to research presented at SLEEP 2023.

Over three in five affected children do not receive mental health services within 6 months of experiencing a firearm injury, according to a study published in Pediatrics.

MIAMI BEACH, Fla. — Treatment with subcutaneous buprenorphine on a weekly or monthly basis eased cravings and withdrawals in those with opioid use disorder, per data from the American Society of Clinical Psychopharmacology annual meeting.

SAN FRANCISCO — A culture-based program improved alcohol use disorder in American Indians, according to a presenter at the American Psychiatric Association annual meeting.

INDIANAPOLIS — Newborns with higher levels of hair cortisol, a measure of fetal cortisol in the last trimester of pregnancy, were more likely to have delayed sleep onset at age 7 months, according to preliminary research.

INDIANAPOLIS — In a survey of psychiatrically hospitalized youth, more than half of participants reported their most recent suicide attempt occurred in the evening and night. According to researchers, the diurnal variation in suicidal ideation points to the need for increased support in the later hours of the day to decrease youth suicide risk.

MIAMI BEACH, Fla. — Treatment with KarXT reduced symptom severity for those with schizophrenia and acute psychosis compared with placebo, according to research presented at the American Society of Clinical Psychopharmacology annual meeting.